HPV Prevention and Control Board

Short introduction at the Sixth HPV Prevention and Control Board meeting 15-16/11/2018 Bogota, Colombia.



www.hpvboard.org

Unique expertise: inspired on the Viral Hepatitis Prevention Board (VHPB)

- ➤ Embedded in the same facilities (University of Antwerp, Centre for the Evaluation of Vaccination)
- Based on a similar way of working
- > Same scientific secretariat team
- ➤ More than 25 years of support to the control and prevention of Viral Hepatitis in Europe:
 - Support implementation of WHO recommendations related to Viral Hepatitis
 - Organising discussion forum and meetings (very fast if needed) with experts on Viral Hepatitis
 - Rapid response on Viral Hepatitis issues that can affect public health
 - Bringing together organisations working on Viral Hepatitis
- Network of advisors in the broad field of Viral Hepatitis
- Dissemination platform



www.vhpb.org



VHPB News | About us | Meetings | Publications | Resources | Links | Contact us

search

Recent meetings

- ▶ 2016 March, Ljubljana, Slovenia
- ▶ 2015 November Riga, Latvia
- ▶ 2015 June London, UK

Recent publications

► Global progress in the control of viral hepatitis and acceptable delay in Hepatitis B immunication

Human Vaccines & Immunotherapeutics 2016, DOI:10.1080/21645515.2016.1177689

► Long-term Protection After Hepatitis B Vaccine

J Infect Dis. 2016, doi: 10.1093/infdis/jiv750

Recent newsletters

- ► Prevention and control of viral hepatitis in the Baltio States: lessons learnt and the way forward
- ► Towards a hepatitis-free Europe: how to make it feasible and affordable
- ► Burden and prevention of viral hepatitis in Arotic region

News - World Health Assembly (WHA) endorsed WHO's first Global Health Sector Strategy on viral hepatitis for 2016-2021

On 28 May 2016, representatives from the WHO Member States convening the Sixty-minth World Health Assembly unanimously endorsed the Global Health Sector Strategy (GHSS) on viral hepatitis for 2016-2021.

Aim of the strategy: spur countries to action in order to eliminate hepatitis as a public health threat by 2030.

More info

Read more

News - May is Hepatitis Awareness Month

In the United States, May is Hepetatis Awareness Month. The 19th of May is Hepatitis Testing Day.

For more info:

- CDC hepatitis website
- follow on twitter



Read more

News - Report on Innovative Financing into Hepatitis B and C Prevention and Treatment in Low and Middle Income Countries.

VHPB launches report on Innovative Financing into Hep B and C Prevention and Treatment.

Download the:

- Press realease
- Infographio
- Report

Read the blog:

 Eliminating a 'silent killer': innovative sources of financing to help meet costs of prevention and treatment of viral hepatitis
 by Pierre Van Damme.





Prevention and control of Viral Hepatitis in Brazil and other Latin American countries, lessons learnt and the way forward

Brasilia, Brazil, 19-21 March 2014

Meeting Co-organised by

Brazilian Ministry of Health, Brazilian Society of Hepatology, PAHO, Viral Hepatitis Prevention Board

















Mission, Goal & Objectives

1. Mission:

Generate, multiply and disseminate relevant information on HPV to a broad array of stakeholders.

2. Goal:

Contribute to the control of HPV infection and to the prevention and screening of HPV related cancers.

3. Objectives:

Providing evidence based guidance on key technical and strategic issues.

Monitoring the progress of HPV control programs at the country and regional levels.





STRUCTURE

A multi-disciplinary Board formed by prominent experts

- > Act in their personal capacity
- Are often affiliated with stake holding partners
- This provides open and honest discussions
- Advisors and speakers at HPV Prevention & Control Board meetings are not paid
- No formal organisation with president, vice-president etc: minimal bureaucratic structure

Advisors:

- Dr. Marc Arbyn, Scientific Institute of Public
 Health, Belgium
- Prof. dr. Paolo Bonanni, University of Florence, Italy
- Dr. Xavier Bosch, Cataln Institute of Oncology (ICO), Spain
- Dr. Kate Cuschieri, Scottisch HPV Reference
 Laboratory, Royal Infirmary of Edinburgh,
 Scotland, UK

- Dr. Silvia de Sanjosé, Catalan Institute of Oncology (ICO), Spain
- Prof. dr. Eduardo Franco, McGill University, Canada
- Prof. Dr. Anna Giuliano, Moffitt Cancer Center, USA
- Dr. Mark Kane, Consultant, USA
- Dr. Sharon Hanley, Hokkaido University, Japan



A multi-disciplinary Board formed by prominent experts

Advisors:

- Prof. dr. Mira Kojouharova, National Centre of Infectious and Parasitic Diseases (NCIPD), Bulgaria
- Prof. dr. Susanne Krüger Kjaer, University of Copenhagen, Denmark
- Dr. Heidi Larson, London School of Hygiene and Tropical Medicine, UK
- Prof. dr. Pier Luigi Lopalco, University of Pisa, Italy
- Prof. dr. Nubia Muñoz, Em. Prof of the National Cancer Institute of Colombia
- Prof. dr. Mario Poljak, Institute of Microbiology and Immunology, clinical Microbiology, Slovenia
- Dr. Kevin Pollock, Glasgow Caledonian University, Scotland, UK

- Prof. Dr. Margaret Stanley, University of Cambridge, UK
- Prof. Dr. Pierre Van Damme, University of Antwerp, Belgium
- Dr. Alex Vorsters, University of Antwerp, Belgium
- Dr. Scott Wittet, Consultant, USA

Observers:

- Dr. Iacobo Baussano, IACR
- Dr. Nedret Emiroglu, WHO Euro
- Mr. Tarik Derough, ECDC
- Dr. Liudmila Mosina, WHO Euro
- Dr. Lauri Markowitz, CDC, USA
- Dr. Susan Wang, CDC, USA



Supported by a permanent & dynamic Scientific Secretariat:

- Personnel involved:
 - Brenda Janssens, Xenia Mikulla
 - Greet Hendrickx
 - Alex Vorsters












- Executive Secretary: Pierre Van Damme
- Located within the facilities of the Centre for the Evaluation of Vaccination (CEV), University of Antwerp



Secretariat implements

- Preparation and organisation of meetings
- Publications
- Media activities
- Website: www.hpvboard.org
- Participation in third party meetings
- All financial issues are done by the rules of the University of Antwerp



Permanent intensive communication between HPV board members and secretariat





WAY OF WORKING

Two meetings per year

- 1. Technical meeting (topics: future vaccines, vaccine strategies, booster doses, health economics, screening technologies and strategies, vaccine safety, dealing with anti-vaccine messages, et cetera)
- 2. Country meeting: SWOT analysis of a country or a region



Output of the meetings published:

- HPV Prevention & Control Board website
- International Scientific Journals
- New: Videos of presentations will be made available



Country meeting: 'Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward' 17-18 November 2016, Copenhagen, Denmark





Technical meeting: Symposium: Building Trust, Managing Risk: Vaccine Confidence and Human Papillomavirus Vaccination, 7-8 June 2017, London, UK



Country meeting: 'Prevention and control of HPV and HPV related cancers in Ireland and the UK: lessons learnt and the way forward' 30^{th} November – 1 December 2017, Dublin, Ireland.



As the meeting was held in Dublin, we had the honour to have Mr Simon Harris, Minister of Health of Ireland, open the meeting. In his speech, he reiterated his full support to the HPV vaccination programme in Ireland and emphasized the role of qualified medical professionals



Publications in scientific journals

Papillomavirus Research:

Manuscript on 'Overcoming barriers in HPV vaccination and screening programs'



Papillomavirus Research

Volume 4, December 2017, Pages 45-53 open access



Overcoming barriers in HPV vaccination and screening programs

Alex Vorsters ^a A

, Marc Arbyn ^b, Marc Baay ^c, Xavier Bosch ^d, Silvia de Sanjosé ^d, ^e, Sharon Hanley ^f, Emilie Karafillakis ^g, Pier Luigi Lopalco ^h, Kevin G. Pollock ⁱ, Joanne Yarwood ^j, Pierre Van Damme ^a

Vaccine:

HPV Immunization programs: Ensuring their sustainability and resilience.





Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine



Commentary

HPV immunization programs: Ensuring their sustainability and resilience



Alex Vorsters*, Pierre Van Damme

Centre for the Evaluation of Vaccination, University of Antwerp, Belgium



Table 1
Checklist for countries to strengthen their immunization program, Example of HPV vaccination.

Prior to introduction of HPV immunization program	Countries maintaining a program	In case of a crisis			
Focus on positive effects and impact of vaccination					
Elaborate an action plan: Combine screening and vaccination Include a communication budget Document burden of disease	Implement a monitoring, follow up and adjustment tool to correct communications, training and/or policy if required.	Assign a focal point who deals with the media			
Communication strategy with a focus on:					
One voice Trustworthy websites Use of social media Train the media					
Train HCP on HPV and on how to d	Invest in/restore confidence among HCP and public health staff				
Create political support and reach out to silent supporters of the vaccine		Engage professional networks and enhance political support			
Develop and (at regular intervals) te					
Develop a monitoring, follo	Develop a monitoring, follow up and adjustment tool				
Define the right age for vaccination	Take alleged side-effects seriously: Show empathy Early response is essential Don't be complacent Do not think problems will go away by themselves, they may get worse				



www.hpvboard.org





Home	About us .	Meetings	Resources	Vaccine safety	News	
S2 17 10 17 1						

You are here: UAntwerp > Projects > HPV Prevention and Control Board > Meetings

Meetings

- > Building Trust, Managing Risk: Vaccine Confidence and Human Papillomavirus Vaccination -June 2017
- > Prevention and control of HPV and HPV related cancers in Denmark: lessons learnt and the way forward - November 2016
- Barriers in HPV vaccination & cervical screening programmes
 June 2016
- Kick off meeting December 2015
- Workshops in international conferences

HPV Prevention and Control Board meetings

The Board organizes two meetings per year, one with a focus on technical issues, the second on a SWOT analysis of a country/region. Technical meetings include topics such as newer vaccines, vaccine safety, comparison of vaccine strategies, the need for booster doses, health economics, immunization of males, impact of vaccine on non-cervical diseases such as head and neck and anal cancers, screening technologies and strategies, dealing with anti-vaccine messages, etcetera. Country meetings take place in key countries and regions. Here, the Board invites local health authorities to present data on coverage of screening and immunization as well as impact and control strategies.

Workshops in international conferences

The HPV Prevention and Control Board also organizes workshops at international conferences

Workshops in international conferences

Contact

HPV Prevention and Control Board Executive Secretariat

Campus Drie Eiken Universiteitsplein 1 2610 Wilrijk België Tel. +32 (0)3 265 26 64 info@hpvboard.org

Last update: 30/06/2017



The role of HCP in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania, 15 & 16 May 2018

Short Videos



Benefits and Safety of HPV Vaccination
- Dr. Xavier Bosch



USA - Helping healthcare providers improve HPV communication - Dr. Noel Brewer



 Newsletter was distributed with links to the meeting page and short videos.





Updates 1/2018

Email not displaying correctly?

View it in your browser



The presentations of our most recent HPV Board meeting entitled "The role of Health Care Providers (HCP) in HPV vaccination and screening programme implementation - Prevention and control of HPV and HPV related cancers in Romania" are now available on our website.

The meeting received the support of the MOH, and we were very fortunate to have the Romanian Health Minister Sorina Pintea attending (see picture above).



Meeting background document

Preliminary background document 'Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward'

15 November – 16 November 2018, Bogota, Colombia

Content

Introduction		3
Purpose of th	he background document	3
Part 1: Prese	ntation related references by session	4
Session 2	The Health Care Systems in Colombia	5
Session 3	Epidemiology of HPV and cervical cancer screening in Colombia	10
Session 4	Prevention and control of HPV in Colombia	23
Part 2: Biblio	graphy of Speakers	30
	y of HPV vaccines. Assessments from the Global Advisory Committee on Vaccine S by Patrick Zuber provided to the MOH, and other stake holders in Colombia	
	Action Plan for Cervcial Cancer Prevention and Control 2018-2030. Provisional Ag 6th Directing Council, 70th Session of the Regional Committee of WHO for the An	nericas.
•••••		56







70th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 23-27 September 2018

Provisional Agenda Item 4.5

CD56/9 11 July 2018 Original: English

PLAN OF ACTION FOR CERVICAL CANCER PREVENTION AND CONTROL 2018-2030







70th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 23-27 September 2018

16. The goal is to accelerate progress toward the elimination of cervical cancer as a public health problem in the Americas by reducing incidence and mortality rates by one-third by 2030. This goal is aligned with Target 3.4 of the Sustainable Development Goals.⁶

Goal	Impact indicator	Baseline (2012 latest year available)	Target (2030)
Reduce cervical cancer incidence and mortality in	Cervical cancer incidence rate ^a	14.9/100,000 women ^a	10.0/100,000 women
the Americas by one-third, by 2030	Cervical cancer mortality rate ^a	5.8/100,000 women ^a	3.9/100,000 women

a. Source: International Agency for Research on Cancer. Estimated cancer incidence, mortality, and prevalence worldwide, 2012 [cited Jan 4 2018]. Available from: http://globocan.iarc.fr/Pages/fact_sheets population.aspx







70th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 23-27 September 2018

16. The goal is to accelerate progress toward the elimination of cervical cancer as a public health problem in the Americas by reducing incidence and mortality rates by one-third by 2030. This goal is aligned with Target 3.4 of the Sustainable Development Goals.⁶

Goal	Impact indicator	Baseline (2012 latest year available)	Target (2030)	Baseline Colombia
Reduce cervical cancer incidence and mortality in	Cervical cancer incidence rate ^a	14.9/100,000 women ^a	10.0/100,000 women	18,7/100,000 women
the Americas by one-third, by 2030	Cervical cancer mortality rate ^a	5.8/100,000 women ^a	3.9/100,000 women	8/100,000 women

a. Source: International Agency for Research on Cancer. Estimated cancer incidence, mortality, and prevalence worldwide, 2012 [cited Jan 4 2018]. Available from: http://globocan.iarc.fr/Pages/fact_sheets population.aspx







70th SESSION OF THE REGIONAL COMMITTEE OF WHO FOR THE AMERICAS

Washington, D.C., USA, 23-27 September 2018

Strategic Lines of Action

- 17. The Plan identifies the following four strategic lines of action:
- Improve cervical cancer program organization and governance, information systems, and cancer registries;
- Strengthen primary prevention through information, education, and HPV vaccination;
- Improve cervical cancer screening and precancer treatment through innovative strategies; and
- d) Improve access to services for cancer diagnosis, treatment, rehabilitation, and palliative care.









Prevention and control of HPV and HPV related cancers in Colombia: Lessons learnt and the way forward. Meeting objectives:

- Give an overview of the health care systems in Colombia.
- Provide a summary of the epidemiology, burden of disease and surveillance related to HPV and HPV related cancers in Colombia.
- Discuss successes, topical issues and challenges related to HPV vaccination and screening particular to Colombia.
- Review country examples from Latin America to learn from their successes and challenges.
- Gain insight in the various stakeholder perspectives.
- Propose recommendations for the way forward.



Thank you.

